International Stem Cell Corporation is a California-based biotechnology company developing novel stem cell based therapies and biomedical products. ISCO’s core technology, parthenogenesis, creates pluripotent human stem cells from unfertilized eggs. These stem cells avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care.